Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board
Summary
DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts from UCLA, Johns Hopkins, Harvard/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, among others. “Our SaaS platform enables, among others, researchers and drug developers to optimize drug design, improve clinical trial effectiveness, rapidly explore repurposing of compounds, refine FDA label strategies and improve product life cycle management - thus creating substantial ROI for our clients.” Ameet Nathwani, MD, is Chairman of the newly created MSAB, which will initially consist of five members that represent industry, specialty medical societies, regulatory, data science and patient advocacy. DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs.